# Antiseizure Medication (ASM) Choice Protocol

## Clinical Guidelines for Selection and Management

**Version:** 1.0
**Last Updated:** December 2025
**Evidence Sources:** ILAE, AAN/AES, NICE NG217, ESETT Trial

---

## Table of Contents

1. [Introduction](#1-introduction)
2. [Seizure Classification](#2-seizure-classification)
3. [First-Line ASM Selection by Seizure Type](#3-first-line-asm-selection-by-seizure-type)
4. [Special Populations](#4-special-populations)
5. [Status Epilepticus Protocol](#5-status-epilepticus-protocol)
6. [Drug Interactions](#6-drug-interactions)
7. [Adverse Effects Profile](#7-adverse-effects-profile)
8. [Dosing Guidelines](#8-dosing-guidelines)
9. [Monitoring Parameters](#9-monitoring-parameters)
10. [Treatment Algorithm](#10-treatment-algorithm)
11. [References](#11-references)

---

## 1. Introduction

### 1.1 Purpose

This protocol provides evidence-based guidance for antiseizure medication (ASM) selection across all patient populations and seizure types. It integrates recommendations from major international guidelines including ILAE, AAN/AES, and NICE.

### 1.2 Terminology

Per ILAE 2024 recommendations, the term **"antiseizure medication" (ASM)** replaces "antiepileptic drug" (AED) to accurately reflect that these medications control seizures but do not cure epilepsy.

### 1.3 General Principles

| Principle | Description |
|-----------|-------------|
| **Monotherapy first** | Initial treatment should aim for monotherapy |
| **Start low, go slow** | Begin at low dose and titrate gradually |
| **Seizure type matters** | ASM selection must match seizure classification |
| **Individualize** | Consider comorbidities, age, sex, and drug interactions |
| **Reassess regularly** | Evaluate efficacy and tolerability at each visit |

---

## 2. Seizure Classification

### 2.1 ILAE 2017 Operational Classification

```
SEIZURE ONSET
├── FOCAL ONSET
│   ├── Aware
│   │   ├── Motor onset (automatisms, atonic, clonic, epileptic spasms, hyperkinetic, myoclonic, tonic)
│   │   └── Non-motor onset (autonomic, behavior arrest, cognitive, emotional, sensory)
│   ├── Impaired Awareness
│   │   ├── Motor onset
│   │   └── Non-motor onset
│   └── Focal to bilateral tonic-clonic
│
├── GENERALIZED ONSET
│   ├── Motor
│   │   ├── Tonic-clonic
│   │   ├── Clonic
│   │   ├── Tonic
│   │   ├── Myoclonic
│   │   ├── Myoclonic-tonic-clonic
│   │   ├── Myoclonic-atonic
│   │   ├── Atonic
│   │   └── Epileptic spasms
│   └── Non-motor (Absence)
│       ├── Typical
│       ├── Atypical
│       ├── Myoclonic
│       └── Eyelid myoclonia
│
└── UNKNOWN ONSET
    ├── Motor (tonic-clonic, epileptic spasms)
    └── Non-motor (behavior arrest)
```

### 2.2 Epilepsy Syndromes Relevant to ASM Selection

| Syndrome | Age of Onset | Key Features | Preferred ASM |
|----------|--------------|--------------|---------------|
| **Childhood Absence Epilepsy (CAE)** | 4-10 years | Typical absences, 3 Hz spike-wave | Ethosuximide, Valproate |
| **Juvenile Myoclonic Epilepsy (JME)** | 12-18 years | Morning myoclonus, GTC, absences | Valproate, Levetiracetam, Lamotrigine |
| **Juvenile Absence Epilepsy (JAE)** | 10-17 years | Absences less frequent than CAE | Valproate, Lamotrigine |
| **Lennox-Gastaut Syndrome** | 1-7 years | Multiple seizure types, slow spike-wave | Valproate, Lamotrigine, Rufinamide |
| **Dravet Syndrome** | <1 year | Prolonged febrile seizures, SCN1A | Valproate, Clobazam, Stiripentol |
| **Temporal Lobe Epilepsy** | Any | Focal with impaired awareness | Lamotrigine, Levetiracetam, Carbamazepine |

---

## 3. First-Line ASM Selection by Seizure Type

### 3.1 Focal Seizures (Adults)

| Evidence Level | Medication | Notes |
|----------------|------------|-------|
| **Level B** (Should consider) | **Lamotrigine** | SANAD II supports as first-line; good tolerability |
| **Level C** (May consider) | **Levetiracetam** | Rapid titration possible; watch for psychiatric effects |
| **Level C** (May consider) | **Zonisamide** | Weight-neutral; once-daily dosing |
| Alternative | Oxcarbazepine | Less enzyme induction than carbamazepine |
| Alternative | Carbamazepine | Effective but enzyme inducer |
| Alternative | Lacosamide | Good tolerability; cardiac monitoring needed |

**SANAD II Trial Key Finding:** Lamotrigine demonstrated superiority to levetiracetam for time to treatment failure in focal epilepsy.

### 3.2 Focal Seizures (Elderly ≥60 years)

| Evidence Level | Medication | Notes |
|----------------|------------|-------|
| **Level B** | **Lamotrigine** | Preferred; minimal drug interactions |
| **Level C** | **Gabapentin** | No hepatic metabolism; renal dosing needed |
| Preferred | **Levetiracetam** | Minimal interactions; dose reduce for renal function |
| Alternative | Lacosamide | Good tolerability; avoid in cardiac conduction issues |

**⚠️ Avoid in Elderly:**
- Phenytoin (cognitive effects, drug interactions, narrow therapeutic window)
- Phenobarbital (sedation, cognitive impairment)
- Carbamazepine (hyponatremia risk, enzyme induction)

### 3.3 Focal Seizures (Pediatric)

| Age Group | First-Line | Second-Line |
|-----------|------------|-------------|
| **Infants (<1 year)** | Levetiracetam | Phenobarbital, Oxcarbazepine |
| **Children (1-12 years)** | Oxcarbazepine, Levetiracetam | Lamotrigine, Carbamazepine |
| **Adolescents (12-18 years)** | Lamotrigine, Levetiracetam | Oxcarbazepine, Lacosamide |

### 3.4 Generalized Tonic-Clonic Seizures

| Population | First-Line | Notes |
|------------|------------|-------|
| **Males** | Valproate | Most effective for GTC |
| **Females of childbearing potential** | Levetiracetam, Lamotrigine | Avoid valproate |
| **Elderly** | Levetiracetam, Lamotrigine | Avoid valproate (tremor, weight) |
| **Pediatric** | Valproate, Levetiracetam | Consider syndrome |

### 3.5 Absence Seizures

| Syndrome | First-Line | Second-Line | Avoid |
|----------|------------|-------------|-------|
| **Childhood Absence Epilepsy** | Ethosuximide*, Valproate* | Lamotrigine | Carbamazepine, Oxcarbazepine, Phenytoin, Gabapentin, Pregabalin, Vigabatrin |
| **Juvenile Absence Epilepsy** | Valproate, Lamotrigine | Levetiracetam | Same as above |

*Level B evidence: Ethosuximide or valproate should be considered before lamotrigine for CAE

### 3.6 Myoclonic Seizures

| First-Line | Second-Line | Avoid (May Exacerbate) |
|------------|-------------|------------------------|
| Valproate | Levetiracetam | Carbamazepine |
| Levetiracetam | Clonazepam | Oxcarbazepine |
| | Zonisamide | Phenytoin |
| | Topiramate | Gabapentin |
| | | Pregabalin |
| | | Vigabatrin |

**⚠️ Note:** Lamotrigine may occasionally exacerbate myoclonic seizures (NICE NG217)

### 3.7 Tonic and Atonic Seizures

| First-Line (Level C) | Adjunctive Options |
|---------------------|-------------------|
| Lamotrigine | Rufinamide (Lennox-Gastaut) |
| Valproate | Clobazam |
| | Felbamate (with caution) |
| | Cannabidiol |

### 3.8 Unknown Onset Seizures

When seizure type cannot be determined:

| Situation | Recommended ASM |
|-----------|-----------------|
| **Likely focal** | Lamotrigine, Levetiracetam |
| **Likely generalized** | Valproate (males), Levetiracetam (females) |
| **Truly unknown** | Levetiracetam, Valproate, Lamotrigine |

**Broad-spectrum ASMs (effective for multiple seizure types):**
- Valproate
- Levetiracetam
- Lamotrigine
- Topiramate
- Zonisamide
- Perampanel

---

## 4. Special Populations

### 4.1 Pregnancy

#### 4.1.1 Teratogenicity Risk Classification

| Risk Category | ASM | MCM Rate | Notes |
|---------------|-----|----------|-------|
| **Lowest Risk** | Levetiracetam | 2-3% | Preferred in pregnancy |
| **Lowest Risk** | Lamotrigine | 2-3% | Monitor levels; dose may need increase |
| **Low Risk** | Oxcarbazepine | 2-3% | Alternative option |
| **Moderate Risk** | Carbamazepine | 4-6% | Neural tube defects, craniofacial anomalies |
| **High Risk** | Topiramate | 3-5% | Oral clefts; 2.5x ID risk |
| **Highest Risk** | Valproate | 5-15% | **CONTRAINDICATED** in pregnancy |

*MCM = Major Congenital Malformations; ID = Intellectual Disability*

#### 4.1.2 Neurodevelopmental Risks (2024 Data)

| ASM | Autism Risk | Intellectual Disability | ADHD |
|-----|-------------|------------------------|------|
| **Valproate** | 30-40% NDD risk | Significantly increased | Increased |
| **Topiramate** | Increased | 2.5x increased | - |
| **Carbamazepine** | 1.25x increased | 1.30x increased | - |
| **Lamotrigine** | No significant increase | No significant increase | No significant increase |
| **Levetiracetam** | No significant increase | No significant increase | No significant increase |

*NDD = Neurodevelopmental Disorders*

#### 4.1.3 Pregnancy Management Protocol

```
PRE-CONCEPTION (Ideal: 6-12 months before)
├── Switch from high-risk ASM to lamotrigine or levetiracetam
├── Optimize to lowest effective dose
├── Folic acid 4-5 mg/day (high dose if on enzyme inducers)
└── Genetic counseling if appropriate

FIRST TRIMESTER
├── Continue lowest effective ASM dose
├── Avoid valproate and topiramate
├── Monthly ASM level monitoring (especially lamotrigine)
└── Detailed fetal ultrasound at 11-14 weeks

SECOND/THIRD TRIMESTER
├── ASM level monitoring every 4-8 weeks
├── Increase dose if levels drop significantly (lamotrigine ↓40-60%)
├── Anatomy scan at 18-22 weeks
└── Growth scans as indicated

PERIPARTUM
├── Consider IV access for ASM administration
├── Continue ASM; do not skip doses
├── Vitamin K 10 mg IM to neonate if on enzyme inducers
└── Breastfeeding generally safe (except barbiturates, high-dose benzodiazepines)

POSTPARTUM
├── Reduce dose if increased during pregnancy (within 2-3 weeks)
├── Monitor for seizure breakthrough
└── Sleep deprivation precautions
```

#### 4.1.4 Preferred Combinations in Pregnancy

Based on 2024 evidence:
- **Lamotrigine + Levetiracetam:** 60% lower MCM risk than valproate monotherapy
- Avoid combining known teratogens (carbamazepine + valproate + topiramate)

### 4.2 Elderly (≥65 years)

#### 4.2.1 Preferred ASMs in Elderly

| ASM | Advantages | Considerations |
|-----|------------|----------------|
| **Levetiracetam** | No hepatic metabolism, minimal interactions, IV available | Psychiatric effects, renal dosing |
| **Lamotrigine** | Good tolerability, minimal cognitive effects | Slow titration, rash risk |
| **Gabapentin** | No hepatic metabolism, no interactions | Renal dosing, TID dosing |
| **Lacosamide** | Good tolerability, BID dosing | PR prolongation, avoid in cardiac disease |

#### 4.2.2 Dosing Adjustments for Elderly

| ASM | Standard Adult Dose | Elderly Starting Dose | Notes |
|-----|---------------------|----------------------|-------|
| Levetiracetam | 500 mg BID | 250 mg BID | Adjust for CrCl |
| Lamotrigine | 25 mg daily | 25 mg daily | Same titration, may need lower maintenance |
| Gabapentin | 300 mg TID | 100-300 mg daily | CrCl-based dosing |
| Lacosamide | 50 mg BID | 50 mg BID | Max 300 mg/day in elderly |

#### 4.2.3 ASMs to Avoid or Use Cautiously in Elderly

| ASM | Reason to Avoid |
|-----|-----------------|
| Phenytoin | Cognitive effects, drug interactions, osteoporosis |
| Phenobarbital | Sedation, cognitive impairment, enzyme induction |
| Carbamazepine | Hyponatremia (SIADH), cardiac effects, interactions |
| Oxcarbazepine | Higher hyponatremia risk than carbamazepine |
| Topiramate | Cognitive slowing, word-finding difficulty |
| Valproate | Tremor, weight gain, thrombocytopenia |

### 4.3 Renal Impairment

#### 4.3.1 ASMs Requiring Dose Adjustment

| ASM | Renal Elimination | Dose Adjustment |
|-----|-------------------|-----------------|
| **Levetiracetam** | 66% unchanged | CrCl 30-50: 50-75% dose; CrCl <30: 50% dose; HD: supplement |
| **Gabapentin** | 100% unchanged | CrCl 30-60: 50% dose; CrCl 15-30: 25% dose; HD: supplement |
| **Pregabalin** | 98% unchanged | CrCl 30-60: 50% dose; CrCl 15-30: 25% dose |
| **Lacosamide** | 40% unchanged | Mild/Moderate: no change; Severe: max 300 mg/day |
| **Topiramate** | 70% unchanged | CrCl <70: 50% dose |
| **Brivaracetam** | 8% unchanged | No adjustment needed |

#### 4.3.2 ASMs Safe in Renal Impairment (No Adjustment Needed)

| ASM | Notes |
|-----|-------|
| Carbamazepine | Hepatic metabolism |
| Valproate | Hepatic metabolism |
| Phenytoin | Hepatic metabolism (but altered protein binding) |
| Lamotrigine | Hepatic glucuronidation |
| Clobazam | Hepatic metabolism |

### 4.4 Hepatic Impairment

#### 4.4.1 Preferred ASMs in Hepatic Disease

| ASM | Hepatic Metabolism | Safety in Hepatic Impairment |
|-----|-------------------|------------------------------|
| **Levetiracetam** | Minimal | **Preferred** - safe |
| **Gabapentin** | None | **Preferred** - safe |
| **Pregabalin** | None | **Preferred** - safe |
| **Lacosamide** | Moderate | Use with caution; max 300 mg/day in severe |
| Brivaracetam | Partial | Reduce dose in severe impairment |

#### 4.4.2 ASMs to Avoid in Hepatic Impairment

| ASM | Reason |
|-----|--------|
| Valproate | Hepatotoxic; fatal liver failure risk |
| Phenytoin | Highly protein-bound; unpredictable levels |
| Carbamazepine | Hepatic metabolism; can worsen liver function |
| Felbamate | Hepatotoxicity risk |
| Phenobarbital | Hepatic metabolism; prolonged half-life |

### 4.5 Psychiatric Comorbidities

#### 4.5.1 ASM Selection Based on Psychiatric Condition

| Psychiatric Condition | Preferred ASM | Consider Avoiding |
|----------------------|---------------|-------------------|
| **Depression** | Lamotrigine (mood stabilizer) | Levetiracetam, Phenobarbital, Topiramate |
| **Anxiety** | Pregabalin, Gabapentin | Levetiracetam (may worsen) |
| **Bipolar Disorder** | Valproate, Lamotrigine, Carbamazepine | - |
| **Psychosis** | Avoid high-risk ASMs | Levetiracetam, Topiramate |
| **ADHD** | Carbamazepine, Lamotrigine | Phenobarbital |
| **Suicidal ideation** | Careful monitoring all ASMs | Levetiracetam, Topiramate |

**⚠️ FDA Warning:** All ASMs carry increased suicidality risk (OR 1.8); monitor closely especially in first 6 months.

### 4.6 Cardiac Conditions

#### 4.6.1 ASMs and Cardiac Effects

| Cardiac Consideration | Avoid | Preferred |
|----------------------|-------|-----------|
| **AV Block / Bradycardia** | Lacosamide, Carbamazepine, Phenytoin | Levetiracetam, Valproate |
| **Long QT Syndrome** | Phenytoin, Lacosamide | Levetiracetam, Valproate |
| **Heart Failure** | - | Levetiracetam (no cardiac effects) |
| **Anticoagulation (warfarin)** | Enzyme inducers | Levetiracetam, Gabapentin |

---

## 5. Status Epilepticus Protocol

### 5.1 Definition

- **Status Epilepticus (SE):** Seizure lasting >5 minutes OR ≥2 seizures without full recovery between
- **Refractory SE:** Continues despite first-line and second-line treatment
- **Super-refractory SE:** Continues ≥24 hours after anesthetic treatment initiation

### 5.2 Treatment Algorithm

```
TIME 0-5 MIN: STABILIZATION
├── ABCs (Airway, Breathing, Circulation)
├── IV access, O2, monitors
├── Fingerstick glucose → treat hypoglycemia
├── Thiamine 100 mg IV (if malnutrition/alcohol suspected)
└── Labs: glucose, electrolytes, ASM levels, toxicology

TIME 5-20 MIN: FIRST-LINE (Benzodiazepines)
├── OPTION 1: IV Lorazepam 0.1 mg/kg (max 4 mg/dose)
│   └── May repeat x1 in 5-10 min
├── OPTION 2: IM Midazolam 10 mg (>40 kg) or 5 mg (13-40 kg)
│   └── Preferred if no IV access
├── OPTION 3: IV Diazepam 0.15-0.2 mg/kg (max 10 mg/dose)
│   └── May repeat x1
└── OPTION 4: Rectal Diazepam 0.2-0.5 mg/kg (max 20 mg) if no IV/IM

TIME 20-40 MIN: SECOND-LINE (Established SE)
├── If seizures continue after adequate benzodiazepine:
│
├── OPTION 1: Fosphenytoin 20 mg PE/kg IV (max 150 mg PE/min)
│   ├── Cardiac monitoring required
│   └── Avoid in known cardiac disease
│
├── OPTION 2: Valproate 40 mg/kg IV (max 3000 mg; rate 3-6 mg/kg/min)
│   ├── Avoid in pregnancy, liver disease
│   └── Preferred in generalized epilepsy
│
├── OPTION 3: Levetiracetam 60 mg/kg IV (max 4500 mg; over 15 min)
│   ├── Safe in cardiac, hepatic disease
│   └── Preferred in neonates with cardiac disorders
│
└── OPTION 4: Phenobarbital 15-20 mg/kg IV (if above unavailable)
    └── Respiratory depression risk

TIME 40-60 MIN: REFRACTORY SE (Third-Line)
├── Repeat second-line agent at 50% dose OR
├── Add different second-line agent OR
└── Proceed to anesthetic therapy:
    ├── Midazolam infusion: 0.2 mg/kg bolus → 0.1-2 mg/kg/hr
    ├── Propofol: 2 mg/kg bolus → 2-5 mg/kg/hr
    ├── Pentobarbital: 5-15 mg/kg → 0.5-3 mg/kg/hr
    └── ICU admission, continuous EEG monitoring required

>60 MIN: SUPER-REFRACTORY SE
├── Continue anesthetic infusion with EEG monitoring
├── Target burst-suppression for 24-48 hours
├── Add maintenance ASMs
├── Consider: ketamine, inhaled anesthetics, immunotherapy
└── Investigate underlying etiology
```

### 5.3 ESETT Trial Key Findings (2020)

The Established Status Epilepticus Treatment Trial demonstrated:

| Agent | Dose | Seizure Cessation | Conclusion |
|-------|------|-------------------|------------|
| Fosphenytoin | 20 mg PE/kg | 45% | No significant difference |
| Valproate | 40 mg/kg | 46% | between the three agents |
| Levetiracetam | 60 mg/kg | 47% | for second-line treatment |

**Clinical Implication:** Choice among these three agents can be based on patient-specific factors (comorbidities, current ASMs, side effect profile).

### 5.4 Pediatric Status Epilepticus

| Time | Treatment | Dose |
|------|-----------|------|
| 0-5 min | Stabilization | ABCs, glucose, access |
| 5-10 min | Lorazepam IV | 0.1 mg/kg (max 4 mg) |
| | OR Midazolam IM | 0.2 mg/kg (max 10 mg) |
| | OR Diazepam rectal | 0.5 mg/kg (max 20 mg) |
| 10-20 min | Repeat benzodiazepine | Same dose x1 |
| 20-40 min | Fosphenytoin | 20 mg PE/kg |
| | OR Valproate | 40 mg/kg |
| | OR Levetiracetam | 60 mg/kg |
| | OR Phenobarbital | 20 mg/kg |
| >40 min | Anesthetic therapy | ICU, continuous EEG |

### 5.5 Neonatal Status Epilepticus (ILAE 2023)

| Line | Agent | Dose | Notes |
|------|-------|------|-------|
| **First-line** | Phenobarbital | 20-40 mg/kg IV | Preferred regardless of etiology |
| **First-line (channelopathy)** | Phenytoin or Carbamazepine | Standard doses | If channelopathy suspected |
| **Second-line** | Phenytoin | 20 mg/kg IV | - |
| | Levetiracetam | 40-60 mg/kg IV | Preferred if cardiac disorder |
| | Midazolam | 0.15 mg/kg then infusion | - |
| | Lidocaine | 2 mg/kg then infusion | Avoid if cardiac issues |

---

## 6. Drug Interactions

### 6.1 CYP450 Enzyme Effects

#### 6.1.1 Strong Enzyme Inducers

| ASM | Enzymes Induced | Clinical Impact |
|-----|-----------------|-----------------|
| **Phenobarbital** | CYP1A2, 2C9, 2C19, 3A4, UGT | Reduces levels of most other drugs |
| **Phenytoin** | CYP1A2, 2C9, 2C19, 3A4, UGT | Reduces levels of most other drugs |
| **Carbamazepine** | CYP1A2, 2C9, 3A4, UGT | Reduces levels of most other drugs |
| **Primidone** | Same as phenobarbital | Metabolized to phenobarbital |

#### 6.1.2 Moderate/Weak Enzyme Inducers

| ASM | Enzymes Induced | Clinical Impact |
|-----|-----------------|-----------------|
| **Oxcarbazepine** | CYP3A4 (weak) | Reduces oral contraceptive efficacy |
| **Topiramate** (≥200 mg/day) | CYP3A4 | Reduces oral contraceptive efficacy |
| **Eslicarbazepine** | CYP3A4 (weak) | Reduces oral contraceptive efficacy |
| **Felbamate** | CYP3A4 (weak) | Also inhibits CYP2C19 |
| **Rufinamide** | CYP3A4 (weak) | Modest induction |

#### 6.1.3 Enzyme Inhibitors

| ASM | Enzymes Inhibited | Clinical Impact |
|-----|-------------------|-----------------|
| **Valproate** | CYP2C9, UGT | Increases lamotrigine, phenobarbital levels |
| **Felbamate** | CYP2C19, β-oxidation | Increases phenytoin, valproate levels |
| **Stiripentol** | CYP1A2, 2C19, 3A4 | Multiple drug interactions |
| **Cannabidiol** | CYP2C19, 3A4 | Increases clobazam metabolite |

#### 6.1.4 No Significant CYP Interactions

| ASM | Notes |
|-----|-------|
| **Levetiracetam** | Preferred when polypharmacy |
| **Gabapentin** | No hepatic metabolism |
| **Pregabalin** | No hepatic metabolism |
| **Lacosamide** | Minimal CYP involvement |
| **Brivaracetam** | Minimal CYP involvement |

### 6.2 Important Drug-Drug Interactions

#### 6.2.1 ASM-ASM Interactions

| Combination | Effect | Management |
|-------------|--------|------------|
| Valproate + Lamotrigine | LTG level ↑↑ (2-3x) | Reduce LTG dose 50%; slow titration |
| Carbamazepine + Lamotrigine | LTG level ↓↓ | Increase LTG dose |
| Phenytoin + Valproate | Complex: PHT free ↑, total ↓ | Monitor free PHT level |
| Carbamazepine + Valproate | CBZ-epoxide ↑ (toxicity) | Monitor for CBZ toxicity |
| Felbamate + Valproate | VPA level ↑ | Reduce VPA dose |
| Cannabidiol + Clobazam | N-desmethylclobazam ↑↑ | Reduce clobazam dose |

#### 6.2.2 ASM-Non-ASM Interactions

| ASM | Interacting Drug | Effect | Management |
|-----|------------------|--------|------------|
| **Enzyme inducers** | Oral contraceptives | Contraceptive failure | Use ≥50 mcg ethinyl estradiol or alternative method |
| **Enzyme inducers** | Warfarin | Reduced anticoagulation | INR monitoring; dose adjustment |
| **Enzyme inducers** | DOACs | Reduced efficacy | Avoid combination or use alternative |
| **Enzyme inducers** | Statins | Reduced efficacy | May need dose increase |
| **Enzyme inducers** | Immunosuppressants | Subtherapeutic levels | Use non-inducing ASM |
| **Enzyme inducers** | Chemotherapy | Reduced efficacy | Use non-inducing ASM |
| **Valproate** | Carbapenem antibiotics | VPA level ↓↓ (75-90%) | **AVOID combination** |
| **Carbamazepine** | Macrolide antibiotics | CBZ toxicity | Monitor; use azithromycin |
| **Carbamazepine** | Azole antifungals | CBZ toxicity | Monitor CBZ level |
| **Gabapentin** | Antacids | Gabapentin ↓ 20% | Separate by 2 hours |

### 6.3 Contraceptive Considerations

| ASM Category | Effect on Hormonal Contraceptives | Recommendation |
|--------------|-----------------------------------|----------------|
| **Strong inducers** (PHT, PB, CBZ, PRM) | Significant reduction in efficacy | IUD, depot medroxyprogesterone, or barrier methods |
| **Moderate inducers** (OXC, TPM ≥200 mg, ESL) | Reduced efficacy | Same as above |
| **No effect** (VPA, LEV, LTG, GBP, PGB, LCM, BRV) | No reduction | Standard contraceptives OK |
| **Lamotrigine** | OCs reduce LTG levels 40-60% | Adjust LTG dose with OC changes |

---

## 7. Adverse Effects Profile

### 7.1 Common Adverse Effects by ASM

| ASM | Common Effects | Serious/Rare Effects | Monitoring |
|-----|----------------|----------------------|------------|
| **Levetiracetam** | Somnolence, irritability, behavioral changes | Psychosis (rare) | Mood/behavior |
| **Lamotrigine** | Rash, headache, dizziness | SJS/TEN (slow titration reduces risk) | Rash (first 8 weeks) |
| **Valproate** | Weight gain, tremor, hair loss, GI upset | Hepatotoxicity, pancreatitis, teratogenicity | LFTs, ammonia, CBC |
| **Carbamazepine** | Dizziness, diplopia, ataxia, hyponatremia | SJS/TEN (HLA-B*1502), aplastic anemia | HLA-B*1502 (Asian), CBC, Na |
| **Oxcarbazepine** | Hyponatremia, dizziness, fatigue | SJS/TEN | Sodium levels |
| **Phenytoin** | Gingival hyperplasia, hirsutism, ataxia | SJS/TEN, osteoporosis, cerebellar atrophy | Drug level, vitamin D |
| **Phenobarbital** | Sedation, cognitive impairment | Dependence, paradoxical hyperactivity (children) | Drug level |
| **Topiramate** | Cognitive slowing, paresthesias, weight loss | Kidney stones, metabolic acidosis, glaucoma | Bicarbonate, renal function |
| **Zonisamide** | Drowsiness, anorexia, cognitive effects | Kidney stones, oligohidrosis (children) | Renal function |
| **Gabapentin** | Sedation, weight gain, peripheral edema | None significant | - |
| **Pregabalin** | Sedation, weight gain, peripheral edema | None significant | - |
| **Lacosamide** | Dizziness, diplopia, nausea | PR prolongation | ECG (baseline, titration) |
| **Perampanel** | Dizziness, somnolence, aggression | Psychiatric effects | Mood/behavior |
| **Brivaracetam** | Somnolence, dizziness | Psychiatric effects (less than LEV) | Mood/behavior |
| **Clobazam** | Sedation, drooling | Tolerance, dependence | - |
| **Felbamate** | Insomnia, weight loss, headache | Aplastic anemia, hepatic failure | CBC, LFTs (frequent) |
| **Vigabatrin** | Fatigue, weight gain | Visual field defects (irreversible) | Visual fields every 3 months |

### 7.2 Idiosyncratic Reactions Requiring Genetic Testing

| ASM | HLA Allele | Population | Reaction |
|-----|------------|------------|----------|
| **Carbamazepine** | HLA-B*15:02 | Han Chinese, Thai, Malaysian, Filipino, Indian | SJS/TEN |
| **Oxcarbazepine** | HLA-B*15:02 | Same as above | SJS/TEN |
| **Phenytoin** | HLA-B*15:02 | Same as above | SJS/TEN |
| **Carbamazepine** | HLA-A*31:01 | European, Japanese | DRESS, SJS/TEN, MPE |
| **Lamotrigine** | HLA-B*15:02 | Han Chinese (weaker association) | SJS/TEN |

**Recommendation:** HLA-B*15:02 testing before carbamazepine/oxcarbazepine in at-risk populations.

### 7.3 Weight Effects

| Weight Gain | Weight Neutral | Weight Loss |
|-------------|----------------|-------------|
| Valproate | Lamotrigine | Topiramate |
| Carbamazepine | Levetiracetam | Zonisamide |
| Gabapentin | Lacosamide | Felbamate |
| Pregabalin | Oxcarbazepine | |
| Vigabatrin | Phenytoin | |
| | Brivaracetam | |

### 7.4 Cognitive Effects

| Minimal Cognitive Effects | Moderate Effects | Significant Effects |
|---------------------------|------------------|---------------------|
| Lamotrigine | Carbamazepine | Topiramate |
| Levetiracetam | Valproate | Phenobarbital |
| Gabapentin | Oxcarbazepine | Phenytoin (chronic) |
| Lacosamide | | Benzodiazepines |
| Brivaracetam | | |

---

## 8. Dosing Guidelines

### 8.1 Adult Dosing Reference

| ASM | Starting Dose | Titration | Target/Maintenance | Maximum |
|-----|---------------|-----------|-------------------|---------|
| **Levetiracetam** | 250-500 mg BID | ↑500 mg/day every 2 weeks | 1000-1500 mg BID | 3000 mg/day |
| **Lamotrigine** (no VPA) | 25 mg daily | Week 1-2: 25 mg/day; Week 3-4: 50 mg/day; ↑50 mg every 1-2 weeks | 100-200 mg BID | 400-600 mg/day |
| **Lamotrigine** (with VPA) | 25 mg every other day | Week 1-2: 25 mg QOD; Week 3-4: 25 mg/day; ↑25-50 mg every 2 weeks | 50-100 mg BID | 200 mg/day |
| **Valproate** | 250 mg BID | ↑250 mg every 3-7 days | 500-1000 mg BID | 60 mg/kg/day |
| **Carbamazepine** | 100-200 mg BID | ↑200 mg/day weekly | 400-600 mg BID | 1600 mg/day |
| **Oxcarbazepine** | 300 mg BID | ↑300 mg/day weekly | 600-1200 mg BID | 2400 mg/day |
| **Phenytoin** | 100 mg TID or 300 mg QHS | Adjust per levels | Per therapeutic level | Per level |
| **Lacosamide** | 50 mg BID | ↑50 mg BID weekly | 100-200 mg BID | 400 mg/day |
| **Topiramate** | 25 mg daily | ↑25-50 mg/day weekly | 100-200 mg BID | 400 mg/day |
| **Zonisamide** | 100 mg daily | ↑100 mg every 2 weeks | 200-400 mg daily | 600 mg/day |
| **Gabapentin** | 300 mg TID | ↑300 mg/day every 3-7 days | 300-600 mg TID | 3600 mg/day |
| **Pregabalin** | 50-75 mg BID | ↑150 mg/day weekly | 150-300 mg BID | 600 mg/day |
| **Perampanel** | 2 mg QHS | ↑2 mg every 2 weeks | 4-8 mg QHS | 12 mg/day |
| **Brivaracetam** | 25-50 mg BID | ↑25-50 mg BID weekly | 50-100 mg BID | 200 mg/day |
| **Clobazam** | 5 mg daily | ↑5 mg every 5-7 days | 10-20 mg BID | 40 mg/day |

### 8.2 Therapeutic Drug Monitoring

| ASM | Therapeutic Range | When to Monitor |
|-----|-------------------|-----------------|
| **Phenytoin** | 10-20 mcg/mL (total); 1-2 mcg/mL (free) | Baseline, after dose changes, drug interactions, pregnancy |
| **Carbamazepine** | 4-12 mcg/mL | After dose changes, suspected toxicity |
| **Valproate** | 50-100 mcg/mL | Baseline, after dose changes, suspected toxicity |
| **Phenobarbital** | 15-40 mcg/mL | After dose changes, suspected toxicity |
| **Lamotrigine** | 3-14 mcg/mL | Pregnancy (monthly), drug interactions |
| **Levetiracetam** | 12-46 mcg/mL | Adherence concerns, renal impairment |
| **Lacosamide** | 5-10 mcg/mL | Rarely needed |
| **Oxcarbazepine** (MHD) | 12-35 mcg/mL | Hyponatremia monitoring more important |

---

## 9. Monitoring Parameters

### 9.1 Baseline Evaluations (Before Starting Any ASM)

| Test | Rationale |
|------|-----------|
| CBC with differential | Baseline for bone marrow suppression monitoring |
| Comprehensive metabolic panel | Renal/hepatic function baseline |
| LFTs | Hepatotoxicity risk assessment |
| EKG | Cardiac conduction (especially for lacosamide, carbamazepine) |
| Pregnancy test | Women of childbearing potential |
| HLA-B*15:02 | Asian ancestry before CBZ/OXC/PHT |

### 9.2 ASM-Specific Monitoring

| ASM | Parameter | Frequency |
|-----|-----------|-----------|
| **Valproate** | LFTs, CBC, ammonia | Every 3-6 months |
| **Carbamazepine** | CBC, LFTs, sodium | Every 3-6 months |
| **Oxcarbazepine** | Sodium | Every 3-6 months; more often if symptomatic |
| **Phenytoin** | Drug level, CBC, vitamin D, bone density | Annually; levels as needed |
| **Lacosamide** | EKG | Baseline, after titration |
| **Felbamate** | CBC, LFTs | Every 2 weeks for 1 year, then quarterly |
| **Vigabatrin** | Visual fields | Baseline, every 3 months |
| **Topiramate** | Bicarbonate, renal function | Every 6-12 months |

### 9.3 Pregnancy Monitoring

| Parameter | Frequency |
|-----------|-----------|
| ASM levels (especially lamotrigine) | Monthly during pregnancy, postpartum week 1-2 |
| Fetal ultrasound | 11-14 weeks (NT), 18-22 weeks (anatomy), 28-32 weeks (growth) |
| Alpha-fetoprotein | If on valproate or carbamazepine |
| Folic acid supplementation | Pre-conception through first trimester (4-5 mg/day) |

---

## 10. Treatment Algorithm

### 10.1 General Treatment Approach

```
STEP 1: CONFIRM DIAGNOSIS
├── Epilepsy confirmed by clinical history ± EEG
├── Classify seizure type (focal, generalized, unknown)
└── Identify epilepsy syndrome if possible

STEP 2: ASSESS PATIENT FACTORS
├── Age (pediatric, adult, elderly)
├── Sex and childbearing potential
├── Comorbidities (psychiatric, cardiac, renal, hepatic)
├── Current medications (interaction potential)
└── Patient preferences (dosing frequency, side effects)

STEP 3: SELECT FIRST-LINE ASM
├── Match to seizure type (see Section 3)
├── Consider special populations (see Section 4)
├── Avoid contraindicated ASMs
└── Discuss expectations and side effects

STEP 4: INITIATE AND TITRATE
├── Start low, titrate slowly
├── Target lowest effective dose
└── Monotherapy is the goal

STEP 5: ASSESS RESPONSE (After adequate trial: 2-3 months at therapeutic dose)
│
├── SEIZURE-FREE → Continue current regimen
│   └── Consider driving, lifestyle counseling
│
├── REDUCED SEIZURES but not seizure-free
│   ├── Optimize current ASM (increase dose if tolerated)
│   └── If optimized and still seizing → Step 6
│
└── NO IMPROVEMENT or INTOLERABLE SIDE EFFECTS → Step 6

STEP 6: FIRST MONOTHERAPY FAILURE
├── Option A: Switch to alternative first-line ASM (cross-titration)
└── Option B: Add second ASM (rational polytherapy)
    └── Consider mechanisms of action, interaction profile

STEP 7: SECOND MONOTHERAPY/DUOTHERAPY FAILURE
├── Consider drug-resistant epilepsy (DRE) if failed 2 appropriate ASMs
├── Refer to comprehensive epilepsy center
├── Evaluate for:
│   ├── Surgical candidacy
│   ├── Neurostimulation (VNS, RNS, DBS)
│   └── Dietary therapy (ketogenic diet)
└── Continue to optimize medical therapy

STEP 8: ONGOING MANAGEMENT
├── Regular follow-up (every 3-12 months when stable)
├── Monitor for side effects
├── Reassess need for continued therapy (consider withdrawal after 2+ seizure-free years)
└── Address comorbidities and quality of life
```

### 10.2 ASM Selection Quick Reference

| Seizure Type | First Choice | Alternatives | Avoid |
|--------------|--------------|--------------|-------|
| **Focal** | Lamotrigine, Levetiracetam | OXC, CBZ, LCM, ZNS | - |
| **Focal (elderly)** | Lamotrigine, Levetiracetam, Gabapentin | Lacosamide | PHT, PB, CBZ |
| **GTC** | Valproate (males), LEV/LTG (females) | TPM, ZNS, PER | - |
| **Absence** | Ethosuximide, Valproate | Lamotrigine | CBZ, GBP, PHT, OXC |
| **Myoclonic** | Valproate, Levetiracetam | ZNS, TPM, CLB | CBZ, GBP, PHT, OXC, LTG* |
| **Tonic/Atonic** | Lamotrigine, Valproate | Rufinamide, Clobazam | - |
| **Pregnancy** | Levetiracetam, Lamotrigine | Oxcarbazepine | VPA, TPM |

*LTG may exacerbate myoclonic seizures in some patients

---

## 11. References

### Primary Guidelines

1. **ILAE Guidelines and Reports** - [ilae.org/guidelines](https://www.ilae.org/guidelines/guidelines-and-reports)
   - Treatment of Seizures in the Neonate: Guidelines and Consensus-based Recommendations (2023)
   - Medical Therapies for Epilepsy

2. **AAN/AES Practice Guidelines**
   - [Practice guideline update: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy](https://www.neurology.org/doi/10.1212/WNL.0000000000005755) (2018, reaffirmed 2024)
   - [Practice guideline update: Efficacy and tolerability of the new antiepileptic drugs II: Treatment-resistant epilepsy](https://www.neurology.org/doi/10.1212/WNL.0000000000005756) (2018, reaffirmed 2024)

3. **NICE NG217** - [Epilepsies in children, young people and adults](https://www.nice.org.uk/guidance/ng217) (2022, reaffirmed 2025)

### Key Clinical Trials

4. **SANAD II Trial** - Marson AG, et al. Lancet. 2021
   - Lamotrigine vs levetiracetam vs zonisamide for focal epilepsy
   - Valproate vs levetiracetam for generalized and unclassified epilepsy

5. **ESETT Trial** - Kapur J, et al. N Engl J Med. 2019
   - Fosphenytoin vs valproate vs levetiracetam for established status epilepticus

### Pregnancy and Teratogenicity

6. **Stanford Medicine Study (2024)** - [Newer antiseizure drugs safe for pregnancy](https://med.stanford.edu/news/all-news/2024/12/epilepsy-pregnancy.html)

7. **Antiseizure medication use during pregnancy and children's neurodevelopmental outcomes** - [Nature Communications 2024](https://www.nature.com/articles/s41467-024-53813-1)

8. **Risk of Autism after Prenatal Topiramate, Valproate, or Lamotrigine Exposure** - [NEJM 2024](https://www.nejm.org/doi/full/10.1056/NEJMoa2309359)

9. **Teratogenicity risk with ASM duotherapy** - [PubMed 2024](https://pubmed.ncbi.nlm.nih.gov/38340680/)

### Special Populations

10. **Pharmacologic Considerations in the Treatment of Older Adults With Epilepsy** - [Practical Neurology 2024](https://practicalneurology.com/articles/2024-nov/pharmacologic-considerations-in-the-treatment-of-older-adults-with-epilepsy)

11. **Status Epilepticus Management Updates** - [PMC 2023](https://pmc.ncbi.nlm.nih.gov/articles/PMC10295829/)

### Drug Interactions

12. **CYP3A induction by antiseizure medications: systematic review** - [Epilepsia 2024](https://onlinelibrary.wiley.com/doi/10.1111/epi.17822)

13. **Clinically relevant drug interactions with antiepileptic drugs** - [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC1885026/)

14. **Adverse effects of antiseizure medications: pharmacogenetics and drug interactions** - [Frontiers in Pharmacology 2025](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1584566/full)

---

## Appendices

### Appendix A: Abbreviations

| Abbreviation | Full Term |
|--------------|-----------|
| ASM | Antiseizure Medication |
| BID | Twice daily |
| BRV | Brivaracetam |
| CAE | Childhood Absence Epilepsy |
| CBZ | Carbamazepine |
| CLB | Clobazam |
| CrCl | Creatinine Clearance |
| DRE | Drug-Resistant Epilepsy |
| ESL | Eslicarbazepine |
| ESM | Ethosuximide |
| FBM | Felbamate |
| GBP | Gabapentin |
| GTC | Generalized Tonic-Clonic |
| HD | Hemodialysis |
| JME | Juvenile Myoclonic Epilepsy |
| LCM | Lacosamide |
| LEV | Levetiracetam |
| LFT | Liver Function Tests |
| LTG | Lamotrigine |
| MCM | Major Congenital Malformations |
| NDD | Neurodevelopmental Disorders |
| OXC | Oxcarbazepine |
| PB | Phenobarbital |
| PE | Phenytoin Equivalents |
| PER | Perampanel |
| PGB | Pregabalin |
| PHT | Phenytoin |
| PRM | Primidone |
| QHS | At bedtime |
| QOD | Every other day |
| RUF | Rufinamide |
| SE | Status Epilepticus |
| SJS | Stevens-Johnson Syndrome |
| TEN | Toxic Epidermal Necrolysis |
| TID | Three times daily |
| TPM | Topiramate |
| UGT | UDP-Glucuronosyltransferase |
| VGB | Vigabatrin |
| VPA | Valproate/Valproic Acid |
| ZNS | Zonisamide |

### Appendix B: Evidence Levels

| Level | Description |
|-------|-------------|
| **Level A** | Established as effective/ineffective (≥2 Class I studies) |
| **Level B** | Probably effective/ineffective (1 Class I or ≥2 Class II studies) |
| **Level C** | Possibly effective/ineffective (1 Class II or ≥2 Class III studies) |
| **Level U** | Data inadequate or conflicting |

---

*This protocol is intended as a clinical reference and should be used in conjunction with clinical judgment and individual patient assessment. Always consult current prescribing information and local formulary guidelines.*

**Document Control:**
- Created: December 2025
- Review Date: December 2026
- Author: Clinical Protocol Development
- Approval: [Pending institutional review]
